The first-generation EGFR tyrosine kinase inhibitor (EGFR-TKI) reversibly binds to the ATP-binding pocket of EGFR, resulting in EGFR signaling inhibition and tumor growth suppression [2]. Here, EGFR is linked to neoplasm.